Pharma's Market
SPECIAL REPORT
MOST SHARED
- Greek Debt Saga Back on Center Stage for Markets
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- Special Feature: Wall Street History - How Wall Street Got Its Name
- Obama to Project $901 Billion Budget Deficit in 2013
- Private Homebuilders: Dead Men Walking
- When Love and the Fed Collide
- How to Trade the Turmoil in Greece
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- We're Not Greece: Italian Prime Minister Monti
- LinkedIn CEO Calms Post-Lockup Concerns
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- Greek Cabinet Approves EU, IMF Bailout Bill
- We're Not Greece: Italian Prime Minister Monti
- Private Homebuilders in the US: Dead Men Walking
- Dividend Payout Could Hit Record Amount This Year
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- New York Fashion Week Fall 2012
- NetNet: Why Saving Greece Could Destroy the World
- My Funny Valentine: When Love and the Fed Collide
RSS FEED
Merck's Gardasil For Boys: How Will Those Ads Play?
Text Size 
Reporter
 |
CNBC.com photo composite Gardasil |
] has been testing its cervical cancer vaccine Gardasil on young men (16-23 years old). The company says major data on those clinical trials are expected next year and could help Merck win FDA approval of the shots for males as well as females. The first-of-its-kind product has already sparked a sociopolitical controversy with its recommended use for young women. Imagine the brouhaha if or when Merck starts selling it for young men.That effort is getting a shot in the arm (bad, cliche pun intended) today from doctors at the prestigious M.D. Anderson Cancer Center who write a review in the medical journal "Cancer" about HPV-16 (one of the strains of the human papillomavirus that can lead to cancer) being tied to oropharyngeal, or a type of oral cancer.
The researchers conclude, "To hasten the reduction of HPV-16 in the population, widespread vaccination of adolescent and young adult males should also be considered. Although the cervical cancer...prevention policy of the HPV-16/18 (another leading cancer-causing strain) vaccination of young women and adolescent females are commended, we fear that vaccination programs limited to females will only delay the potential benefit in prevention of HPV-16/18-associated oropgaryngeal cancers, which typically occur in men. We encourage the rapid study of the efficacy and safety of these vaccines in males and, if successful, the recommendation of vaccination in young adult and adolescent males." One of the doctors who wrote the article has been a consultant for GSK.
Gardasil is well on its way to becoming a major blockbuster for Merck. GlaxoSmithKline [GSK
Loading...
()
] is awaiting FDA approval (for females) of a similar vaccine called Cervarix.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
